Advertisement

Topics

FDA's Off-Patent, Off-Exclusivity List Draws Few Takers Early On

19:13 EDT 4 Aug 2017 | SCRIP

US agency has received 'very few' inquiries about the drugs on the list since its release.

      

Related Stories

 

Original Article: FDA's Off-Patent, Off-Exclusivity List Draws Few Takers Early On

NEXT ARTICLE

More From BioPortfolio on "FDA's Off-Patent, Off-Exclusivity List Draws Few Takers Early On"

Quick Search
Advertisement